Cargando…

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination

Detalles Bibliográficos
Autor principal:	Vadrevu, Krishna Mohan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084887/ https://www.ncbi.nlm.nih.gov/pubmed/37163147 http://dx.doi.org/10.1016/j.lansea.2023.100198

Ejemplares similares

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster – authors' reply
por: Rose, Winsley, et al.
Publicado: (2023)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022)

Influence of overstated abstract conclusions on clinicians: a web-based randomised controlled trial
por: Shinohara, Kiyomi, et al.
Publicado: (2017)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Unsparing self-critique strengthens the field, but Bailey et al. overstate the ‘problems with delay discounting’
por: Stein, Jeffrey S., et al.
Publicado: (2023)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Overstating the consequences of radiographic abnormalities.
por: Flynn, J Jay, et al.
Publicado: (2004)

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
por: Janssen, Cécile, et al.
Publicado: (2022)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Physician characteristics associated with proper assessment of overstated conclusions in research abstracts: A secondary analysis of a randomized controlled trial
por: Tsujimoto, Yasushi, et al.
Publicado: (2019)

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
por: Tay, Matthew Zirui, et al.
Publicado: (2023)

AEs after homologous versus heterologous COVID-19 booster
Publicado: (2022)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study
por: Flores-Lastra, Nancy, et al.
Publicado: (2023)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
por: Prayongrat, Anussara, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
por: Liu, Xinxue, et al.
Publicado: (2021)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
por: Kang, Chun-Min, et al.
Publicado: (2022)

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2022)

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
por: Honfi, Dániel, et al.
Publicado: (2022)

Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes
por: Fraleigh, Nya L., et al.
Publicado: (2019)

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
por: Khoo, Nicholas Kim Huat, et al.
Publicado: (2022)

Does the homologous booster with the inactivated coronavirus disease 2019 vaccine work for the omicron variant? Real-world evidence from Jilin, China
por: Guo, Jun, et al.
Publicado: (2023)

Faulty Conclusions
por: Neely, W. Brock
Publicado: (1994)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
por: Gianserra, Laura, et al.
Publicado: (2022)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
por: Wei, Yunhua, et al.
Publicado: (2022)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o5i69nlfnu3lsv5mkq6uipgmh0